期刊文献+

浸润性乳腺癌不同分子亚型p53与EGFR的表达及相关性分析 被引量:6

Correlation analysis between p53 and EGFR expression in distinct molecular subtypes of invasive breast cancer
下载PDF
导出
摘要 目的分析浸润性乳腺癌不同分子亚型中p53与表皮生长因子受体(EGFR)的表达情况及其相关性。方法回顾性分析山东省肿瘤医院2012年1月至2013年8月264例可手术乳腺癌患者的临床及病理资料,分析分子亚型与临床病理特征的相关性及不同分子亚型中p53与EGFR表达的相关性。结果乳腺癌分子亚型与发病年龄、初潮年龄无统计学差异(均P>0.05)。分子亚型与是否绝经、肿瘤直径、淋巴结转移、病理分期、细胞角蛋白5/6(CK5/6)、p53及EGFR表达状况具有统计学差异(均P<0.05)。Luminal型乳腺癌患者T1期所占比例多于non-Luminal型乳腺癌患者(P<0.05)。p53与EGFR总体表达呈正相关(r=0.226,P<0.05),进一步分层分析显示各分子亚型中只有三阴性乳腺癌(TNBC)中p53与EGFR表达呈正相关(r=0.319,P<0.05),其他亚型中p53与EGFR表达无相关性(均P>0.05)。结论 p53与EGFR在TNBC中表达呈正相关,探讨二者的表达有助于进一步了解TNBC的分子生物学特征,并为TNBC的治疗提供新的思路。 Objective To investigate the correlation between p53 and EGFR overexpression in distinct molecular subtypes of invasive breast cancer. Methods The clinicopathology data of 264 operable breast cancer patients from January 2012 to August 2013 were retrospectively analyzed, and the correlation of p53 and epidermal growth factor receptor ( EGFR) expression in distinct molecular subtypes was investigated. Results No statistically significant differences were found among distinct molecular subtypes regarding age at diagnosis and age at menarche by using chisquare test(allP 〉0. 05). Statistically significant differences were found among distinct molecular subtypes regarding menopause status, tumor size, lymph node status, pathological stage , Cytokeratin 5/6 (CK5/6), p53 and EGFR (all P〈0. 05). There were more patients with T1 stage in Luminal sub-type than that of in non-luminal subtype (P〈0. 05). p53 expression had a positive correlation with EGFR expression in invasive breast cancer (r=0. 226,P〈0. 05). There was a significant positive correction between p53 and EGFR in triple-negative breast cancer (TNBC) by stratification analysis (r=0. 319,P〈0. 05), not in other subtypes(all 〉0. 05). Conclusions There was a positive correlation between p53 and EGFR in TNBC. P53 and EGFR in TNBC may help us to comprehensively recognize the molecular biological characteristics of TNBC,and may offer us a new idea to TNBC treatment.
出处 《中国肿瘤外科杂志》 CAS 2015年第2期78-82,共5页 Chinese Journal of Surgical Oncology
基金 山东省自然科学基金(ZR2012HL34)
关键词 乳腺肿瘤 分子亚型 免疫组织化学 P53 EGFR EGFR breast cancer molecular subtype immunohistochemistry EGFR
  • 相关文献

参考文献18

  • 1李春艳,王培,张晟,刘艳,张瑾.三阴性乳腺癌的临床病理特征和预后分析[J].中华肿瘤杂志,2013,35(6):463-467. 被引量:72
  • 2Grob TJ, HeilenkiStter U, Geist S, et al. Rare oncogenic muta- tions of predictive markers for targeted therapy in triple-negative breast cancer [ J ]. Breast cancer Res Treat, 2012, 134 (2) : 561 -567.
  • 3Dent R, Tmdeau M, Pritchard KI, et al. Triple-negative breast cancer: clinical features and patterns of recurrence [J~. Clin Cancer Res, 2007, 13 ( 15 ) : 4429-4434.
  • 4Hammond MEH, Hayes DF, Dowsett M, et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer (unabridged version) [ J ]. Arch Pathol Lab Med, 2010, 134(7): e48-e72.
  • 5Goldhirsch A, Winer EP, Coates AS, et al. Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013 [ J]. Ann Oncol, 2013, 24 (9): 2206-2223.
  • 6progesterone receptor-positive tumor ceils within immunohistochem- ieally defined luminal A breast cancer[ J]. J Clin Oncol,2013,31 (2) : 203-209.
  • 7Perou CM,Sorlie T, Eisen MB, et al. Molecular portraits of human breast tumour' s [ J ]. Nature,2000,406 (6797) :747-752.
  • 8童钟,李鸿君,朱立新.不同分子亚型可手术乳腺癌患者个体化综合治疗的临床观察[J].中国普通外科杂志,2012,21(11):1353-1356. 被引量:10
  • 9Howland NK, Driver TD, Sedark MP, et al. Lymph node involve- ment in immunohistochemistry-based molecular classifications of breast cancer [ J 1. J Surg Res, 2013,185 ( 2 ) : 697-703.
  • 10Park S, Koo JS, Kim MS, et al. Characteristics and outcomes according to molecular subtypes of breast cancer as classified by a panel of four biomarkers using immunohistochemistry[ J]. Breast, 2012, 21 ( 1 ) : 50-57.

二级参考文献35

  • 1Li XM, Yah H, Zhou KN, et al. Effects of music therapy on pain among female breast cancer patients after radical mastectomy: results from a randomized controlled trial[J]. Breast Cancer Res Treat, 2011,128(2):411-419.
  • 2Maddox WA, Carpenter JT Jr, Laws HL, et al. A randomized prospective trial of radical (Halsted) mastectomy versus modified radical mastectomy in 311 breast cancer patients[J]. Ann Surg, 1983, 198(2):207-212.
  • 3Abdulkarim BS, Cuartero J, Hanson J, et al. Increased risk of locoregional recurrence for women with T1-2N0 triple-negative breast cancer treated with modified radical mastectomy without adjuvant radiation therapy compared with breast-conserving therapy[J]. J Clin Oncol, 2011, 29(21):2852-2858.
  • 4Ellis MJ, Dixon M, Dowsett M, et al. A luminal breast cancer genome atlas: progress and barriers[J]. J Steroid Biochem Mol Biol, 2007. 106(1-5):125-129.
  • 5Sanpaolo P, Barbieri V, Genovesi D. Prognostic value of breast cancer subtypes on breast cancer specific survival, distant metastases and local relapse rates in conservatively managed early stage breast cancer: a retrospective clinical study[J]. Eur J Surg Oncol, 2011, 37(10):876-882.
  • 6Ellis MJ, Coop A, Singh B, et al. Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ErbB-1 and/or ErbB-2-positive, estrogen receptor-positive primary breast cancer: evidence from a phase III randomized trial[J]. J Clin Oncol, 2001, 19(18):3808-3816.
  • 7Stickeler E, Pils D, Klar M, et al. basal-like molecular subtype and HER2 up-regulation and response to neoadjuvant chemotherapy in breast cancer[J]. Oncol Rep, 2011, 26(4):1037-1045.
  • 8Foulkes WD, Brunet JS, Stefansson IM, et al. The prognostic implication of the basal-like (cyclin E high/p27 low/p53+/ glomeruloid-microvascular-proliferation+) phenotype of BRCA1- related breast cancer[J]. Cancer Res, 2004, 64(3):830-835.
  • 9Lehmann BD, Bauer JA, Chen X. et al. Identification of human triple- negative breast cancer subtypes and preclinical models for selection of targeted therapies[J]. J Clin Invest, 2011, 121(7):2750-2767.
  • 10Vrdoljak E, Mise BP, Lukic B, et al. Long-lasting control of triple?negative metastatic breast cancer with the novel drug combination ixabepilone and capecitabine-case report. Onkologie, 2010, 3: 53-56.

共引文献79

同被引文献44

引证文献6

二级引证文献17

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部